Evaluate the safety and immunogenicity of priming with TBC-3B, which consists of live, recombinant vaccinia virus expressing the env and gag/pol genes of HIV-1 strain followed by boosting with HIV-1 recombinant gp120 strain MN vaccine formulated in alum, in healthy HIV-1 uninfected adult voluteers who who have never previously received vaccinia virus. We are currently in the follow up phase of this study.
Showing the most recent 10 out of 515 publications